The cell cycle and its relevance to the urologist

Journal of Urology

Volumn 171, Issue 4, 2004, Pages 1674-1681

  DeWolf, William C ^a   Gaston, Sandra M ^a  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

Apoptosis; Cell cycle; DNA; Proteins; Urologic diseases

Indexed keywords

APOPTOSIS; CELL CYCLE; CELL GROWTH; CELL PROLIFERATION; CELL SURVIVAL; DNA SYNTHESIS; KIDNEY HYPERTROPHY; KIDNEY POLYCYSTIC DISEASE; PRIORITY JOURNAL; PROTEIN SYNTHESIS; REGULATORY MECHANISM; REVIEW; SIGNAL TRANSDUCTION; URINARY TRACT DISEASE;

EID: 1642354309     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.ju.0000115505.95189.24     Document Type: Review

References (55)

1. Evan, G. I. and Vousden, K. H.: Proliferation, cell cycle and apoptosis in cancer. Nature, 411: 342, 2001
2. Lygerou, Z. and Nurse, P.: Cell cycle. License withheld-geminin blocks DNA replication. Science, 290: 2271, 2000
3. Nishitani, H. and Lygerou, Z.: Control of DNA replication licensing in a cell cycle. Genes Cells, 7: 523, 2002
4. Hubbard, S. R.: Crystal structure of the activated insulin receptor tyrosine kinase in complex with peptide substrate and ATP analog. EMBO J, 16: 5572, 1997
5. Huse, M. and Kuriyan, J.: The conformational plasticity of protein kinases. Cell, 109: 275, 2002
6. Maranchie, J. K. and Linehan, W. M.: Genetic disorders and renal cell carcinoma. Urol Clin North Am, 30: 133, 2003
7. Ogawa, H., Ishiguro, K., Gaubatz, S., Livingston, D. M. and Nakatani, Y.: A complex with chromatin modifiers that occupies E2F and Myc-responsive genes in G0 cells. Science, 296: 1132, 2002
8. Hartwell, L. H.: Twenty-five years of cell cycle genetics. Genetics, 129: 975, 1991
9. Oller, A. R., Rastogi, P., Morgenthaler, S. and Thilly, W. G.: A statistical model to estimate variance in long term low dose mutation assays: testing of the model in a human lymphoblastoid mutation assay. Mutat Res, 216: 149, 1989
10. Hollstein, M., Rice, K., Greenblatt, M. S., Soussi, T., Fuchs, R., Sorlie, T. et al: Database of p53 gene somatic mutations in human tumors and cell lines: Nucleic Acids Res, 22: 3551, 1994
11. Hollstein, M., Hergenhahn, M., Yang, Q., Bartsch, H., Wang, Z. Q. and Hainaut, P.: New approaches to understanding p53 gene tumor mutation spectra. Mutat Res, 431: 199, 1999
12. Mutoh, M., Lung, F. D., Long, Y. Q., Roller, P. P., Sikorski, R. S. and O'Connor, P. M.: A p21 (Waf1/Cip1) carboxyl-terminal peptide exhibited cyclin-dependent kinase-inhibitory activity and cytotoxicity when introduced into human cells. Cancer Res, 59: 3480, 1999
13. Okhi, R., Nemoto, J., Murasawa, H., Oda, E., Inazawa, J., Tanaka, N. et al: Reprimo, a new candidate mediator of the p53-mediated cell cycle arrest at the G2 phase. J Biol Chem, 275: 22627, 2000
14. Laronga, C., Yang, H. Y., Neal, C. and Lee, M. H.: Association of the cyclin-dependent kinases and 14-3-3 sigma negatively regulates cell cycle progression. J Biol Chem, 275: 23106, 2000
15. Deng, C., Zhang, P., Harper, J. W., Elledge, S. J. and Leder, P.: Mice lacking p21CIP1/WAF1 undergo normal development, but are defective in G1 checkpoint control. Cell, 82: 675, 1995
16. Guis, D. R., Ezhevsky, S. A., Becker-Hapak, M., Nagahara, H., Wei, M. C. and Dowdy, S. F.: Transduced p16INK4a peptides inhibit hypophosphorylation of the retinoblastoma protein and cell cycle progression prior to activation of Cdk2 complexes in late G1. Cancer Res, 59: 2577, 1999
17. Wang, T. C., Cardiff, R. D., Zuckerberg, L., Lees, E., Arnold, A. and Schmidt, E. V.: Mammary hyperplasia and carcinoma in MMTV-cyclin D1 transgenic mice. Nature, 369: 669, 1994
18. Nobori, T., Miura, K., Wu, D. J., Lois, A., Takabayashi, K. and Carson, D. A.: Deletions of the cyclin-dependent kinase-4 inhibitor gene in multiple human cancers. Nature, 368: 753, 1994
19. Jarrard, D. F., Sarkar, S., Shi, Y., Yeager, T. R., Magrane, G., Kinoshita, H. et al: p16/pRb pathway alterations are required for bypassing senescence in human prostate epithelial cells. Cancer Res, 59: 2957, 1999
20. Pomerantz, J., Schreiber-Agus, N., Liegeois, N. J., Silverman, A., Alland, L., Chin, L. et al: The Ink4a tumor suppressor gene product, p19Arf, interacts with MDM2 and neutralizes MDM2's inhibition of p53. Cell, 92: 713, 1998
21. Kamijo, T., Zindy, F., Roussel, M. F., Quelle, D. E., Downing, J. R., Ashmum, R. A. et al: Tumor suppression at the mouse INK4a locus mediated by the alternative reading frame product p19ARF. Cell, 91: 649, 1997
22. Vousden, K.: p53: death star. Cell, 103: 691, 2000
23. Bartel, F., Taubert, H. and Harris, L. C.: Alternative and aberrant splicing of MDM2 mRNA in human cancer. Cancer Cell, 2: 9, 2002
24. Oliner, J. D., Kinzler, K. W., Meltzer, P. S., George, D. L. and Vogelstein, B.: Amplification of a gene encoding a p53-associated protein in human sarcomas. Nature, 358: 80, 1992
25. Zhang, Y., Xiong, Y. and Yarborough, W. G.: ARF promotes MDM2 degradation and stabilizes p53: ARF-INK4a locus deletion impairs both the Rb and p53 tumor suppression pathways. Cell, 92: 725, 1998
26. Fero, M. L., Randel, E., Gurley, K. E., Roberts, J. M. and Kemp, C. J.: The murine gene p27Kip1 is haplo-insufficient for tumour suppression. Nature, 396: 177, 1998
27. Ponce-Castaneda, M. V., Lee, M. H., Latres, E., Polyak, K., Lacombe, L., Montgomery, K. et al: p27Kip1: chromosome mapping to 12p12-12p13.1 and absence of mutations in human tumors. Cancer Res, 55: 1211, 1995
28. Lu, L., Schulz, H. and Wolf, D. A.: The F-box protein SKP2 mediates androgen control of p27 stability in LNCaP human prostate cancer cells. BMC Cell Biol, 3: 22, 2002
29. Yang, G., Ayala, G., Marzo, A. D., Tian, W., Frolov, A., Wheeler, T. M. et al: Elevated Skp2 protein expression in human prostate cancer: association with loss of the cyclin-dependent kinase inhibitor p27 and PTEN and with reduced recurrence-free survival. Clin Cancer Res, 8: 3419, 2002
30. Cote, R. J., Shi, Y., Groshen, S., Feng, A. C., Cordon-Cardo, C., Skinner, D. et al: Association of p27Kip1 levels with recurrence and survival in patients with stage C prostate carcinoma. J Natl Cancer Inst, 90: 916, 1998
31. Schaefer, D. I., Livanos, E. M., White, A. E. and Tlsty, T. D.: Multiple mechanisms of N-(phosphonoacetyl)-L-aspartate drug resistance in SV40-infected precrisis human fibroblasts. Cancer Res, 53: 4946, 1993
32. Kim, D. and Hermiston, T.: Induction of an oncogenic fusion protein by a viral gene-a new chapter in an old story. Nat Med, 5: 991, 1999
33. Cordon-Cardo, C., Zhang, Z. F., Dalbagni, G., Drobnjak, M., Charytonowicz, E., Hu, S. X. et al: Cooperative effects of p53 and PRB alterations in primary superficial bladder tumors. Cancer Res, 57: 1217, 1997
34. Cioss, S. M., Sanchez, C. A., Morgan, C. A., Schimke, M. K., Ramel, S., Idzerda, R. L. et al: A p53-dependent mouse spindle checkpoint. Science, 267: 1353, 1995
35. Chan, T. A., Hermeking, H., Lengauer, C., Kinzler, K. W. and Vogelstein, B.: 14-3-3Sigma is required to prevent mitotic catastrophe after DNA damage. Nature, 401: 616, 1999
36. Dellambra, E., Golisano, O., Bondanza, S., Siviero, E., Lacal, P., Molinari, M. et al: Downregulation of 14-3-3 sigma prevents clonal evoluation and leads to immortalization of primary human keratinocytes. J Cell Biol, 149: 1117, 2000
37. O'Connor, P. M., Ferris, D. K., Pagano, M., Draetta, G., Pines, J., Hunter, T. et al: G2 delay induced by nitrogen mustard in human cells affects cyclin A/cdk2 and cyclin B1/cdc2-kinase complexes differently. J Biol Chem, 268: 8298, 1993
38. Fukasawa, K., Choi, T., Kuriyama, R., Rulong, S. and Vande Woude, G. F.: Abnormal centrosome amplification in the absence of p53. Science, 271: 1744, 1996
39. Mikhailov, A., Cole, R. W. and Rieder, C. L.: DNA damage during mitosis in human cells delays the metaphase/anaphase transition via the spindle-assembly checkpoint. Curr Biol, 12: 1797, 2002
40. Komarov, P. G., Komarova, E. A., Kondratov, R., Christov-Tselkov, K., Coon, J. S., Chernov, M. V. et al: A chemical inhibitor of p53 that protects mice from the side effects of cancer therapy. Science, 285: 1733, 1999
41. Blagosklonny, M. V. and Pardee, A. B.: Exploting cancer cell cycling for selective protection of normal cells. Cancer Res, 61: 4301, 2001
42. Bhunia, A., Piontek, K., Boletta, A., Liu, L., Qian, F., Xu, P. N. et al: PKD1 induces p21 (Waf1) and regulation of the cell cycle via direct activation of the JAK-STAT signaling pathway in a process requiring PKD2. Cell, 109: 157, 2002
43. Megyesi, J., Price, P. M., Tamayo, E. and Safirstein, R. L.: The lack of a functional p21 (WAF1/CIP1) gene ameliorates progression to chronic renal failure. Proc Natl Acad Sci USA, 96: 10830, 1999
44. Megyesi, J., Andrade, L., Vieira, J. M., Jr., Safirstein, R. L. and Price, P. M.: Coordination of the cell cycle is an important determinant of the syndrome of acute renal failure. Am J Physiol Renal Physiol, 283: F810, 2002
45. Weinstein, I. B.: Disorders in cell circuitry during multistage carcinogenesis: the role of homeostasis. Carcinogenesis, 21: 857, 2000
46. Weinstein, I. B.: Cancer. Addition to oncogenes-the Achilles heal of cancer. Science, 297: 63, 2002
47. Pause, A., Lee, S., Lonergan, K. M. and Klausner, R. D.: The von Hippel-Lindau tumor suppressor gene is required for cell cycle exit upon serum withdrawal. Proc Natl Acad Sci USA, 95: 993, 1998
48. Zatyka, M., da Silva, N. F., Clifford, S. C., Morris, M. R., Wiesener, M. S., Eckardt, K. U. et al: Identification of cyclin D1 and other novel targets for the von Hippel-Lindau tumor suppressor gene by expression array analysis and investigation of cyclin D1 genotype as a modifier in von Hippel-Lindau disease. Cancer Res, 62: 3803, 2002
49. Bindra, R. S., Vasselli, J., Stearman, R., Linehan, W. M. and Lausner, R. D.: VHL mediated hypoxia regulation of cyclin D1 in renal carcinoma cells. Cancer Res, 62: 3014, 2002
50. Gonzalgo, M. L., Hayashida, T., Bender, C. M., Pao, M. M., Tsai, Y. C., Gonzales, F. A. et al: The role of DNA methylation in expression of the p19/p16 locus in human bladder cancer cell lines. Cancer Res, 38: 1245, 1998
51. Chaubert, P., Guillou, L., Kurt, A. M., Bertholet, M. M., Metthez, G., Leisinger, H. J. et al: Frequent p16INK4 (MST1) gene inactivation in testicular germ cell tumors. Am J Pathol, 151: 859, 1997
52. Del Pizzo, J. J., Borkowski, A., Jacobs, S. C. and Kyprianou, N.: Loss of cell cycle regulators p27(Kip1) and cyclin E in transitional cell carcinoma of the bladder correlates with tumor grade and patient survival. Am J Pathol, 155: 1129, 1999
53. Sgambato, A., Migaldi, M., Faraglia, B., Garagnani, L., Romano, G., De Gaetani, C. et al: Loss of P27Kip1 expression correlates with tumor grade and with reduced disease-free survival in primary superficial bladder cancers. Cancer Res, 59: 3245, 1999
54. Tsihlias, J., Kapusta, L. R., DeBoer, G., Morava-Protzner, I., Zbieranowski, I., Bhattacharya, N. et al: Loss of cyclin dependent kinase inhibitor p27Kip1 is a novel prognostic factor in localized human prostate adenocarcinoma. Cancer Res, 58: 542, 1998
55. Kawamata, N., Morosetti, R., Miller, C. W., Park, D., Spirin, K. S., Nakamaki, T. et al: Molecular analysis of the cyclin-dependent kinase inhibitor gene p27/Kip1 in human malignancies. Cancer Res, 55: 2266, 1995